Husch Blackwell is pleased to announce that H. Keeto Sabharwal has joined the firm’s Washington office as a partner on its Intellectual Property Litigation team. He will practice as a member of the firm’s Healthcare, Life Sciences & Education industry group. Sabharwal joins Husch Blackwell from Pillsbury Winthrop Shaw Pittman LLP, where he was a partner in that firm’s Intellectual Property group.

Sabharwal is a seasoned first-chair patent trial lawyer who has litigated intellectual property disputes in a variety of forums, including federal district court (bench and jury trials), the Patent Trial and Appeal Board of the United States Patent and Trademark Office (PTAB), International Trade Commission, and international arbitrations. He has obtained jury verdicts, secured dismissals, and negotiated settlements on behalf of clients. His clients span various industries, including pharmaceuticals, chemicals, medical devices, computer hardware, and software applications, among others.

Sabharwal has particular experience with Abbreviated New Drug Application (ANDA) litigation, where he assists clients seeking to introduce generic competition to the marketplace. He has litigated nearly 50 ANDA cases on behalf of various clients involving many different types of pharmaceutical products and dosage forms, including alogliptin, calcium acetate, carvedilol, colesevelam hydrochloride, dimethyl fumarate, esomeprazole, olanzapine, pioglitazone, and quetiapine fumarate, among many others.

Sabharwal is frequently listed among top patent litigators in various legal directories, including Intellectual Asset Management’s IAM Patent 1000, which remarked that “Sabharwal is a guiding light on Hatch-Waxman litigations complicated by PTAB proceedings.”